Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN....
CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort B during KP.3 and KP.3.1.1 dominant wave CANOPY exploratory clinical efficacy data, to …